introduction
Breast cancer is a heterogeneous disease and gene expression studies have identified molecularly distinct subtypes with prognostic implications across multiple treatment settings [1] [2] [3] .
These subtypes include estrogen receptor (ER)-positiveLuminal A (Luminal A), ER-positive-Luminal B (Luminal B), HER2-enriched (i.e. tumors that overexpress ERBB2-associated genes but do not express genes that define the luminal subtype), basal-like and normal breast-like. HER2-enriched and basal-like subtypes are hormone receptor negative and have poor prognosis [1, 4, 5] .
The immunohistochemical (IHC) evaluation of ER, progesterone receptor (PgR), Ki-67 and HER2 may be considered a surrogate means for identifying the molecular subtypes of breast cancer [6] .
Moreover, a recent head-to-head comparison of a four IHC biomarker panel of ER, PgR, HER2 and Ki-67 (IHC 4) has been shown to provide prognostic information, which could be considered at least equivalent to the genomic health recurrence score [7] .
The IHC classification according to the four subtypes (Luminal A, Luminal B, HER2 and triple negative) appeared useful to define different prognostic subgroups in relationship with the different adjuvant treatments previously received [8] .
Recommendations for selection of adjuvant systemic treatments in specific patient populations were recently proposed based on the recognition of intrinsic biological subtypes with different responses to systemic and local therapies [9] .
Luminal B is characterized by higher grade as well as lower levels of ER-related genes and is characterized by having increased expression of HER2-associated genes (i.e. ERBB2 and GRB7) and a cell proliferation signature that includes the expression of MKI67, CCNB1 and MYBL2, which have been associated with tamoxifen resistance [2, 10] .
Nevertheless, the Luminal B subtype still represents a heterogeneous group of breast cancers, if considered that only 30% of Luminal B tumors present an overexpression of HER2 including both the PgR-positive and PgR-negative disease.
PgR is a prognostic factor, although its prognostic value after long-term follow-up is considered weak and lose [11] . The absence of PgR may be a marker of aberrant growth factor signaling and, consequently, one mechanism for anti-estrogen resistance [12, 13] . ER+/PgR− tumors as defined by RNA profiling represent a distinct subset of breast cancer with aggressive features and poor outcome despite being clinically ER+ [14] .
In order to get a deeper insight into the prognostic significance of subtypes of early breast cancer, we analyzed data according to PgR and HER2 status from a large series of well-characterized patients with breast cancer defined as Luminal B by IHC classification.
patients and methods
We collected information on all consecutive breast cancer patients who underwent breast surgery at the European Institute of Oncology between January 1997 and December 2005. Data on each patient's medical history, concurrent diseases, surgery, pathological evaluation and results of staging procedures (blood chemistry, hematological values, bone scan, chest film and upper abdominal ultrasound examination) were retrieved. The surgically removed breast lesions were thoroughly sampled for pathological examination.
Tissue sections from all previous needle biopsies (at least three sections/ core, cut at 110-200 mm intervals) and from all surgical resections carried out elsewhere were reviewed. Tumors were classified histologically according to the World Health Organization Histological Classification of Breast Tumors, as modified by Rosen and Obermann [15] . Tumor grading was assessed according to Elston and Ellis [16] . We looked for peritumoral vascular invasion as recommended by Rosen and Obermann [17] . Microinvasive breast cancer was diagnosed according to the TNM classification and following the criteria of Rosen and Obermann [15] . ER and PgR status, Ki-67 labeling index determined with the MIB1 monoclonal antibody, and HER2/neu overexpression were evaluated immunohistochemically as previously reported [17] . In particular, HER2/ neu overexpression was evaluated using a 1/800 dilution of a polyclonal antiserum (Dako, Glostrup, Denmark) and considering only complete and intense membrane staining of at least 10% of neoplastic cells as evidence of overexpression (3+). Tumors showing weak to moderate circumferential membrane immunoreactivity (2+) were further subjected to FISH assays for the assessment of gene amplification, as previously reported. For evaluation of ER, PgR status and Ki-67 labeling index, the percentage of cells exhibiting definite nuclear staining over 2000 neoplastic cells examined at ×400 magnification was recorded. The stained slides were evaluated independently by two of the authors. Only nuclear immunoreactivity was evaluated for ER, PgR and MIB1. The threshold for ER and PgR positivity was 1% [17] . Histological grade and biological features were evaluated on the invasive component of the tumor.
statistics
The Fisher's exact test and the Mantel-Haenszel chi-square test for trend were used to assess the association between categorical and ordinal variables, respectively. The primary end-points were the incidence of locoregional relapse (LRR), distant metastases (DM), breast cancer-related survival (BCS) and overall survival (OS).
LRR included ipsilateral breast cancer, breast cancer recurrence in the axilla, regional lymph nodes, chest wall and skin of ipsilateral breast. DM included all sites of recurrence except locoregional relapses and contralateral breast cancer as first of subsequent events. BCS included locoregional relapses, distant metastases, contralateral breast cancer or death from breast cancer. OS was determined as the time from surgery until the date of death (from any cause) or was censored at the date of last follow-up.
Cumulative incidence and survival plots were drawn using the Kaplan-Meier method.
We decided to focus our analysis on the Luminal B subtype defined as tumors with hormonal receptors positive (ER > 0 or PgR > 0) and [Ki-67 ≥ 14% or HER2 overexpressed/amplified (HER2+)].
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We evaluated four subgroups within the Luminal B subtype according to HER2 expression and PgR status: Patients' characteristics are shown in Table 1 .
Triple positive tumors (ER+/PgR+/HER2+) were associated with very young age (<35 years), occurrence of peritumoral vascular invasion and poorer differentiation than other Luminal B subgroups. Finally, TP tumors were associated with more advanced tumor stage, namely with more extensive nodal involvement and larger tumor size than the other Luminal B subgroups About 50% of patients in the Luminal B subtype received only endocrine therapy as adjuvant treatment and 2% of patients did not receive any adjuvant treatment. Patients with ER+/PgR+/HER2+ and ER+/PgR−/HER2+ tumors received more chemotherapy than the other two subgroups without overexpression of HER2. The ER+/PgR+/HER2− subgroup was treated with less chemotherapy and more endocrine therapy alone than the other subgroups ( Table 2) .
About 99% of patients with TP tumors did not receive trastuzumab as adjuvant treatment, while two patients received adjuvant trastuzumab in the subgroup ER+/PgR−/HER2+.
The ER+/PgR+/HER2− subgroup was the one with the lowest rate of LRR, DM and breast cancer-related events as well as with the best BCS and OS when compared with the other Luminal B subgroups (Figures 1 and 2) .
On the contrary, the ER+/PgR−/HER2+ subgroup was the one that showed the worst BCS and OS when compared with the other Luminal B subgroups. At the same time, the TP subgroup showed a better BCS and OS than the ER+/PgR−/ HER2+ but also ER+/PgR−/HER2− subgroup, as shown in Figure 2 .
At (Figure 2) .
At the multivariate analysis, the TP subgroup had an increased risk of locoregional relapses in comparison with the ER+/PgR+/HER2− subgroup but no statistical significant differences could be found for DM, contralateral breast cancer, BCS and OS. On the other hand, the ER+/PgR−/HER2− subgroup was associated with an increased risk with respect to all outcomes considered, including BCS and OS, when compared with the ER+/PgR+/HER2− subgroup. Finally, the analysis showed that the ER+/PgR−/HER2+ subgroup had an increased risk of DM, BCS and OS compared with the ER +/PgR+/HER2− subgroup with HR of 1.93 (1.32-2.83; 95% CI)) and 1.62 (1.14-2.30; 95% CI) for BCS and OS, respectively ( Table 3) .
The multivariate analysis carried out in 1715 women with Luminal B breast cancer treated after 2003, to exclude the potential effect of trastuzumab therapy, confirmed the results obtained in the whole population (Table 4) .
discussion
Subtypes with different epidemiological risk factors, different natural histories and different responses to systemic and local therapies have been identified. Clinicians managing breast cancer should consider cases within the various distinct subtypes in order to properly assess the relevant evidence and reach an appropriate therapeutic choice. Endocrine therapy is part of the treatment of the 'Luminal B' subtype. Chemotherapy is also considered indicated for most patients with 'Luminal B' disease with the addition of trastuzumab in 'HER2-positive' disease [9] .
However, the tumor subtypes identified in these analyses include heterogeneous groups of tumors, and the identification of further tumor subtypes amenable to targeted treatments represents a research priority. Specifically, there is lack of consensus on the threshold indication for inclusion of chemotherapy for patients with 'Luminal B (HER2-negative)' disease.
The results of the present study indicate that PgR is an important prognostic factor in order to properly define subgroups with different prognosis within the Luminal B subtype, irrespective of HER2 overexpression or amplification.
Other studies reported and analyzed the prognostic and predictive role of progesterone receptor in breast cancer, especially of the subgroup of tumors ER+/PgR−.
The prognostic and predictive value of PgR has been for a long time ascribed to the dependence of PgR expression on ER activity, with the absence of the PgR reflecting a nonfunctional ER and resistance to hormonal therapy, However, alternative molecular mechanisms potentially explaining the different outcome and selective estrogen receptor modulator resistance in ER-positive/PgR-negative tumors have been suggested by experimental indications that growth factors may reduce PgR levels. Thus, the absence of PgR may reflect hyperactive cross talk between ER and growth factor signaling pathways that reduce PgR even as they activate other ER functions.
Previous experimental studies have shown that ER+PgR− tumors have high growth factor signaling [12, 18, 19] . In [19] [20] [21] . In the large series of Arpino et al, HER2 overexpression was associated with a significantly shorter disease-free survival (DFS) interval in patients with ER+PgR− tumors, whereas in ER+PgR+ disease, HER2 overexpression was not associated with DFS, among tamoxifen-treated women [19] .
Two large randomized trials evaluated the efficacy of aromatase inhibitors, letrozole (BIG 1-98 trial) and anastrazole (ATAC trial), compared with tamoxifen as adjuvant treatment of patients with early breast cancer. In BIG 1-98, patients treated with letrozole had a better outcome than those treated with tamoxifen regardless of their PgR status [22] . Subsequent analyses of the ATAC trial have shown that quantitative expression of ER and PgR and HER-2 status did not identify patients with differential relative benefit from anastrozole over tamoxifen [23] .
In the present study, we observed that TP breast cancer patients had a better survival than those in the ER+/ PgR−/HER2+ but also in the ER+/PgR−/HER2− subgroup.
The ER+/PgR−/HER2− subgroup received less chemotherapy than TP, so the different survival outcome among these two subgroups could be related to the positive impact of chemotherapy on the risk of breast cancer-related events and deaths in the TP subgroup. However, these data confirm the importance of PgR status, prompting us to consider more chemotherapy in the ER+/PgR−/HER2− subgroup.
About 30% of patients with TP and ER+/PgR−/HER2+ tumors received endocrine therapy alone and ∼65-70% received chemotherapy plus endocrine therapy as adjuvant treatments. Moreover, the same percentage of patients (about 1%) in both the TP and ER+/PgR−/HER2+ subgroups received trastuzumab as adjuvant therapy.
The difference in the outcomes of these two subgroups appeared, therefore, related more probably to the PgR status. In 2003 and during the subsequent years, the use of aromatase inhibitors progressively increased and some patients received trastuzumab as experimental adjuvant treatment. However, multivariate analysis carried out in only the 1715 women with Luminal B breast cancer treated after 2003 confirmed the results obtained in the whole population.
Exploratory analysis of the magnitude of trastuzumab effects within the patient subgroups in the HERA trial showed that adjuvant trastuzumab therapy reduces the risk of relapse similarly across subgroups defined by nodal status and steroid hormone receptor status, even those at relatively low risk for relapse [24] .
Interestingly, in this exploratory analysis of the HERA trial, patients with TP tumors had an important benefit from trastuzumab with 3-year DFS of 85% compared with 77% of patients in the observational arm, and reduction of recurrence risk of 37%. Apparently, the better survival outcome for patients in our analysis compared with the TP patients in the HERA trial can mostly likely be related to the different nodal involvement. About 32% of all patients in the HERA trial did not have nodes involvement; moreover, in the same trial, only the 12%-13% of patients had hormone receptor-positive tumors without nodes involvement. In the present analysis, the number of patients without nodal involvement ranged between 46% with TP tumors and 57% with ER+/PgR−/HER2+ tumors.
Subgroup and retrospective analyses must be interpreted with caution due to the increased likelihood of false-positive and false-negative results arising from the play of chance. However, our data together with the HERA subgroup analysis make us believe not to consider mandatory a triple combination of treatments (endocrine + chemotherapy + anti-HER2 therapy) in all patients with TP tumors, differently from the subgroup of patients with ER+/PgR−/HER2+ tumors.
In conclusion, after dividing the Luminal B subtype group into four subgroups according to PgR and HER2 status, we provided evidence of a relatively good prognosis of the TP subgroup, and highlighted and confirmed the significant impact of progesterone receptor status on the outcome of patients with early breast cancer. 
